Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Viking Therapeutics (NASDAQ: VKTX) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 13-16, 2025, in San Francisco. The company's CEO, Brian Lian, Ph.D., will deliver a corporate presentation on Monday, January 13, 2025, from 1:30 to 2:10 p.m. Pacific time at The Westin St. Francis San Francisco on Union Square.
The presentation will be accessible via live webcast through the Viking Therapeutics website's Investors & Media section under Webcasts. A replay will be available on the company's website after the conference. Dr. Lian will also participate in one-on-one meetings during the event.
Viking Therapeutics is a clinical-stage biopharmaceutical company that specializes in developing novel therapies for metabolic and endocrine disorders.
Positive
- None.
Negative
- None.
News Market Reaction – VKTX
In the trading session that priced this news, VKTX declined 2.05%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Details are as follows:
- 43rd Annual J.P. Morgan Healthcare Conference
Details: Dr. Lian will deliver a corporate presentation and participate in 1-on-1 meetings
Conference dates: January 13-16, 2025
Presentation Timing: 1:30 – 2:10 p.m. Pacific on Monday, January 13, 2025
Location: The Westin St. Francis San Francisco on Union Square; webcast available
A live webcast of the presentation may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts. Additionally, a replay of the webcast will be available on the Viking website following the conference.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. Data from a Phase 1 and a Phase 2 trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 1 trial. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a recently completed Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH; also referred to as metabolic dysfunction associated steatohepatitis, MASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.
For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-present-at-43rd-annual-jp-morgan-healthcare-conference-302340335.html
SOURCE Viking Therapeutics, Inc.